Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Silence Therapeutics Plc ADR (SLN)
Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,546
  • Shares Outstanding, K 29,928
  • Annual Sales, $ 21,650 K
  • Annual Income, $ -50,080 K
  • 60-Month Beta 0.88
  • Price/Sales 8.85
  • Price/Cash Flow N/A
  • Price/Book 8.41
Trade SLN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.54
  • Number of Estimates 1
  • High Estimate -0.54
  • Low Estimate -0.54
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -54.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +7.32%
on 03/30/23
12.38 -47.89%
on 03/01/23
-5.27 (-44.97%)
since 02/28/23
3-Month
6.01 +7.32%
on 03/30/23
16.64 -61.24%
on 12/30/22
-8.93 (-58.06%)
since 12/28/22
52-Week
6.01 +7.32%
on 03/30/23
21.32 -69.75%
on 03/30/22
-12.15 (-65.32%)
since 03/28/22

Most Recent Stories

More News
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics to Buyback siRNA Complement Assets

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

SLN : 6.22 (-1.27%)
OPTN : 2.00 (-0.99%)
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 6.22 (-1.27%)
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics

Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.

DYN : 11.62 (+0.35%)
ACER : 0.7510 (+0.13%)
ASRT : 6.44 (+0.47%)
SLN : 6.22 (-1.27%)
TCRT : 0.6700 (+1.61%)
5 Stocks to Buy as the Drug Industry Bets Big on Innovation

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

DYN : 11.62 (+0.35%)
ACER : 0.7510 (+0.13%)
ASRT : 6.44 (+0.47%)
SLN : 6.22 (-1.27%)
TCRT : 0.6700 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease...

See More

Key Turning Points

3rd Resistance Point 7.75
2nd Resistance Point 7.35
1st Resistance Point 6.82
Last Price 6.22
1st Support Level 5.89
2nd Support Level 5.49
3rd Support Level 4.96

See More

52-Week High 21.32
Fibonacci 61.8% 15.47
Fibonacci 50% 13.66
Fibonacci 38.2% 11.86
Last Price 6.22
52-Week Low 6.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar